Abstract
In the airways, arginase and NOS compete for the common substrate l-arginine. In chronic airway diseases, such as asthma and COPD, elevated arginase expression contributes to airway contractility, hyperresponsiveness, inflammation and remodeling. The disrupted l-arginine homeostasis, through changes in arginase and NOS expression and activity, does not only play a central role in the development of various airways diseases such as asthma or COPD. It possibly also affects l-arginine homeostasis throughout the body contributing to the emergence of co-morbidities. This review focusses on the role of arginase, NOS and ADMA in co-morbidities of asthma and COPD and speculates on their possible connection.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
MeSH terms
-
Animals
-
Anti-Asthmatic Agents / adverse effects
-
Anti-Asthmatic Agents / therapeutic use*
-
Anti-Inflammatory Agents / adverse effects
-
Anti-Inflammatory Agents / therapeutic use*
-
Arginase / antagonists & inhibitors*
-
Arginase / metabolism
-
Asthma / diagnosis
-
Asthma / drug therapy*
-
Asthma / enzymology
-
Asthma / physiopathology
-
Comorbidity
-
Drug Design
-
Enzyme Inhibitors / adverse effects
-
Enzyme Inhibitors / therapeutic use*
-
Humans
-
Lung / drug effects*
-
Lung / enzymology
-
Lung / physiopathology
-
Molecular Targeted Therapy
-
Nitric Oxide / metabolism*
-
Nitric Oxide Synthase / antagonists & inhibitors*
-
Nitric Oxide Synthase / metabolism
-
Pulmonary Disease, Chronic Obstructive / diagnosis
-
Pulmonary Disease, Chronic Obstructive / drug therapy*
-
Pulmonary Disease, Chronic Obstructive / enzymology
-
Pulmonary Disease, Chronic Obstructive / physiopathology
-
Signal Transduction / drug effects
Substances
-
Anti-Asthmatic Agents
-
Anti-Inflammatory Agents
-
Enzyme Inhibitors
-
Nitric Oxide
-
Nitric Oxide Synthase
-
Arginase